Previous 10 | Next 10 |
2024-04-30 08:24:49 ET More on pre-market losers & stocks. Biodexa shares rally 126% on rapamycin licensing deal NewGenIvf signs non-binding term sheet for potential reverse merger with European Wellness Investment Holdings Seeking Alpha’s Quant Rating on ...
2024-04-30 04:49:23 ET Summary On Monday, April 29, Annovis Bio announced their phase 2/3 Alzheimer's Disease trial results, causing stock to drop ~60%. Of the five pre-specified efficacy endpoints, only ADAS-Cog11 results were reported in some details, and only from ~28% of the c...
A look at the top 10 most actives in the United States Tesla Inc. (TSLA) rose 15.3% to $194.05 on volume of 241,483,966 shares SiNtx Technologies Inc. (SINT) rose 34.9% to $0.0545 on volume of 171,893,463 shares Collective Audience Inc. (CAUD) rose 61.6% to $0.6301 on volume of 156,906,40...
2024-04-29 11:17:50 ET Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects Annovis to release efficacy data on Alzheimer's drug in April Annovis Bio falls after Brookline Capital downgrades on PD trial complications Seeking Alpha...
Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD Improvement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as compared to 0.3 for placebo, consistent with our previous Phase II AD/P...
2024-04-28 07:22:26 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
2024-04-27 09:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
2024-04-26 15:00:06 ET More on the markets SPY: The 'Value' From Equities Is Historically Low SPY: The Setup Looks Extremely Bearish Be Greedy When Others Are Fearful, Even If They Are Fearful For A Good Reason BofA watched clients retract $2B last week as th...
2024-04-02 12:53:01 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Annovis Bio (NYSE: ANVS ) just reported results for the fourth quarter of 2023. Annovis Bio reported earnings per share of -$2.33. This was below the analyst estimate for ...
2024-04-02 07:37:07 ET More on Annovis Bio Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects Annovis And Alzheimer's Disease: The Best-Laid Plans Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO Annovis...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food an...
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
2024-07-11 09:15:04 ET H.C. Wainwright analyst issues BUY recommendation for ANVS on July 11, 2024 07:54AM ET. The previous analyst recommendation was Buy. ANVS was trading at $12.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...